Key points are not available for this paper at this time.
Crisaborole, though initially approved for the treatment of mild to moderate atopic dermatitis, has found its application in treatment of various other inflammatory dermatological conditions including psoriasis, vitiligo, stasis dermatitis, inflammatory verrucous epidermal nevus and more. This is due to the involvement of enzyme phosphodiesterase-4 and cyclic adenosine monophosphate (cAMP) in the pathogenesis of these disorders. Sources of study material included PubMed, National Library of Medicine, DermNet, Journal of the American Academy of Dermatology, manufacturer prescribing information and article bibliographies.This review article was prepared to show that crisaborole can be effectively used in treating those inflammatory dermatological disorders (as off-label indications) which are unresponsive to their first line treatment options. The side effects are minimal and tolerable. The only limitation is that the number of studies and case reports with crisaborole are very limited. Crisaborole seems to have promising results in the management of various inflammatory dermatological conditions with minimal side effects.
M. Selvakumar (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: